Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 9/20 | 0.77 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.74 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.71 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.68 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16226456 | 1.00 | GPBAR1 (0.77) | GPBAR1CYP8B1NR1H4CYP3A4PDE3A | |
| SCHEMBL16226920 | 1.00 | GPBAR1 (0.77) | GPBAR1CYP8B1NR1H4CYP3A4PDE3A | |
| SCHEMBL16226236 | 0.93 | GPBAR1 (0.75) | GPBAR1CYP8B1NR1H4CYP3A4PDE3A | |
| SCHEMBL2550233 | 0.93 | GPBAR1 (0.75) | GPBAR1CYP8B1NR1H4CYP3A4PDE3A | |
| SCHEMBL9696816 | 0.93 | GPBAR1 (0.75) | GPBAR1CYP8B1NR1H4CYP3A4PDE3A | |
| SCHEMBL16226693 | 0.93 | GPBAR1 (0.75) | GPBAR1CYP8B1NR1H4CYP3A4PDE3A | |
| SCHEMBL13151646 | 0.93 | GPBAR1 (0.75) | GPBAR1CYP8B1NR1H4CYP3A4PDE3A | |
| SCHEMBL9696820 | 0.93 | GPBAR1 (0.75) | GPBAR1CYP8B1NR1H4CYP3A4PDE3A | |
| SCHEMBL5346761 | 0.93 | GPBAR1 (0.75) | GPBAR1CYP8B1NR1H4CYP3A4PDE3A | |
| SCHEMBL16226534 | 0.93 | GPBAR1 (0.75) | GPBAR1CYP8B1NR1H4CYP3A4PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | GPBAR1 77/4885CYP8B1 557/4885NR1H4 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.